Heyholder
‹ Activism Filings

SHINPOONG PHARMACEUTICAL CO.,LTD Q3 operating loss of KRW 4.4 billion, turning to a loss; revenue KRW 51.3 billion

SHINPOONG PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

Sinpoong Pharm sold KRW 51.3 billion in the third quarter and lost KRW 4.4 billion from its main business, turning from profit to loss versus a year earlier.

Operating profit · 3 months

KRW -4.4 billion

Key facts

Revenue (3 months)
KRW 51.3 billion
Net income (3 months)
KRW -11.8 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 62.6 billion
Revenue (year to date)
KRW 169.7 billion
Operating profit (prior-year 3 months)
KRW 7.2 billion
Operating profit (year to date)
KRW -12.8 billion
Net income (prior-year 3 months)
KRW 6.4 billion
Net income (year to date)
KRW -19.4 billion

Commentary

AI commentary · Not investment advice

What happened

Shinpoong Pharmaceutical filed its quarterly report with consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 51.27 billion. That is 18.1% lower than the same 3 months a year earlier (KRW 62.61 billion). It is also 19.8% lower than the previous quarter.

In the company's terms

Operating profit (money earned from the core business) for the 3 months was a loss of KRW 4.44 billion. A year earlier it was a profit of KRW 7.22 billion, so it turned to a loss. Net income (final profit after taxes and all costs) for the 3 months was a loss of KRW 11.78 billion. A year earlier it was a profit of KRW 6.41 billion, so it also turned to a loss.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 169.68 billion. Operating profit was a loss of KRW 12.84 billion. Net income was a loss of KRW 19.39 billion.

Comments

No comments yet

Comments from shareholders will appear here.